Alzheimer disease: Aβ-independent processes-rethinking preclinical AD

Nature Reviews Neurology

Volumn 9, Issue 3, 2013, Pages 123-124

  Chételat, Gaël ^a  

^a CHU CÔTE DE NACRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; HUMAN; NERVE DEGENERATION; NEUROIMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; BRAIN; BRAIN INJURIES; COGNITION DISORDERS; HUMANS;

EID: 84874948210     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.21     Document Type: Review

References (10)

1. Knopman, D. S. et al. Neuronal injury biomarkers are not dependent on β-amyloid in normal elderly. Ann. Neurol. http://dx.doi.org/10.1002/ana. 23816.
2. Jack, C. R. Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128 (2010).
3. Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292 (2011).
4. Jack, C. R. Jr et al. An operational approach to National Institute on Aging Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 71, 765-775 (2012).
5. Knopman, D. S. et al. Short term clinical outcomes for stages of NIA AA preclinical Alzheimer disease. Neurology 78, 1576-1582 (2012).
6. Jagust, W. J. & Landau, S. M. Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging. J. Neurosci. 32, 18227-18233 (2012).
7. Reiman, E. M. et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case control study. Lancet Neurol. 11, 1048-1056 (2012).
8. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804 (2012).
9. Chételat, G. et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 131, 60-71 (2008).
10. La Joie, R. et al. Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. J. Neurosci. 32, 16265-16273 (2012).